The purpose of this study is to investigate whether TAC plus FOLFOX4 or TACE plus folfox4 are able to improve resection rate and overall survival in patients receiving primary colorectal tumor resection than given FOLFOX4 only.
We administered three cycles FOLFOX4 plus TAC(oxaliplatin,FUDR and MMC) or FOLFOX4 plus TACE(oxaliplatin,FUDR,MMC and embolision) to primary colorectal tumor resected patients with unresected liver metastasis. The study endpoints were resection rate of liver metastasis, progression-free survival, overall survival as evaluated by intent-to-treat analysis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
200
tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml folfox4
tac: oxaliplatin 100mg + fudr 1g + mmc 10mg folfox4
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
RECRUITINGoverall survival
Time frame: 5 years after operation
resection rate of liver metastasis progression-free survival
Time frame: 5 years after operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.